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Carotid Atherosclerotic Plaque Matrix Metalloproteinase-12–Positive
Macrophage Subpopulation Predicts Adverse Outcome After
Endarterectomy
Vincent P. W. Scholtes, MD; Jason L. Johnson, PhD; Nicholas Jenkins, MD; Graciela B. Sala-Newby, PhD; Jean-Paul P. M. de Vries, MD, PhD;
Gert Jan de Borst, MD, PhD; Dominique P. V. de Kleijn, PhD; Frans L. Moll, MD, PhD; Gerard Pasterkamp, MD, PhD; Andrew C. Newby, PhD
Background-—Matrix metalloproteinase-12 (MMP-12) promotes atherosclerosis in animal models. MMP-12 is expressed in only a
subset of foam-cell macrophages (FCMs) in human plaques. We investigated whether the prevalence of this MMP-12–expressing
subpopulation is a prognostic indicator of adverse outcome in patients after carotid endarterectomy (CEA).
Methods and Results-—Serial sections of culprit lesions from 236 patients who underwent CEA and had undergone 3 years of
clinical follow-up were stained immunocytochemically for MMP-12 and for CD68, and the MMP-12/CD68 ratio was used to
quantify the MMP-12–expressing subpopulation. A high MMP-12/CD68 ratio correlated with a high content of lipid and total
macrophages and a low content of vascular smooth muscle cells, as well as with MMP-8 (R=0.211, P=0.001), MMP-9 (R=0.251,
P<0.001), and cleaved caspase-3 (R=0.142, P=0.036) activity measured in a neighboring segment. Dual immunohistochemical
examination conﬁrmed the location of MMP-12 in a subpopulation of MMP-8– and MMP-9–positive FCMs, whereas all apoptotic
FCMs were MMP-12 positive. Patients who yielded plaques within the highest quartile compared with the lowest quartile of
MMP-12/CD68 ratio had a 2.4-fold (hazard ratio, 2.4; 95% CI, 1.1- to 5.1-fold; adjusted P=0.027) increased risk of major adverse
cardiovascular event and a 3.4-fold (3.4; 1.2- to 9.6-fold, P=0.024) increased risk for stroke.
Conclusions-—The prevalence of an MMP-12–positive subset of FCMs is a prognostic marker for adverse clinical outcome after
CEA. ( J Am Heart Assoc. 2012;1:e001040 doi: 10.1161/JAHA.112.001040)
Key Words: atherosclerosis • macrophages • MMP-12 • outcome
T hrombosis due to atherosclerotic plaque rupture remainsthe leading cause of death in Western countries,1
despite currently applied therapies. Furthermore, patients
who have experienced an atherothrombotic event are at
increased risk for another, either in the same territory or
remotely.2,3 Matrix metalloproteinases (MMPs) are a family of
Zn2+-containing proteinases that are believed to play a direct
role in plaque development and rupture.4 Several MMPs
promote an unstable plaque phenotype by destroying the
extracellular matrix of the ﬁbrous cap and facilitating pene-
tration, proliferation, and apoptosis of inﬂammatory cells
including macrophages.5–7 MMP-12 overexpression, in par-
ticular, accelerates lesion development in transgenic rab-
bits8,9; 2 studies in MMP-12 knockout mice demonstrated
reduced plaque growth and beneﬁcial effects on histological
surrogates of plaque instability.5,10 Furthermore, a selective
MMP-12 inhibitor halts atherosclerosis development and
promotes a more stable plaque phenotype in mice.11
MMP-12 is expressed in a subpopulation of foam-cell
macrophages (FCMs) located around the lipid core in human
and rabbit plaques.12–14 Several distinct subpopulations of
FCMs are found in plaques,15 of which one was based on
staining positive for MMP-14 and negative for tissue inhibitor
of metalloproteinase-3.16 Some of these subpopulations are
thought to promote plaque instability, whereas others may be
atheroprotective.15 However, it is not been shown previously
whether the occurrence of any of these subpopulations is
predictive of adverse outcome.
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Our group has pioneered the concept that some biochem-
ical and cellular characteristics of culprit plaques carry
predictive value for future events.17–19 Of relevance, we
previously showed that tissue levels of MMP-8 and MMP-9 in
culprit plaques retrieved after carotid endarterectomy (CEA)
are associated with increased risk of major adverse cardio-
vascular events (MACEs) during clinical follow-up, whereas
MMP-2 levels predicted reduced risk.20,21 This study inves-
tigated whether prevalence of the MMP-12–positive FCM
subpopulation predicts clinical outcome after endarterec-
tomy.
Methods
Patients and Plaques
Plaques were obtained from patients who underwent carotid
endarterectomy (CEA) and were part of the Athero-Express
Biobank.22 Culprit lesions from 236 patients were chosen
from 499 available patients who had undergone CEA within
2002–2006 and who had known follow-up and measure-
ments of MMP-2, MMP-8, MMP-9, and cleaved caspase-3
activity levels. The cohort consisted of 236 randomly
selected patients. To increase the event rate, we have
inserted extra cases, resulting into a total of 55 cases and
181 controls. A case was deﬁned as a person who had
experienced a major adverse cardiovascular event (MACE).
Follow-Up and Clinical Outcome
All patients had undergone a 3-year follow-up after CEA,
including yearly visits to the outpatient clinic and duplex
ultrasound investigations. Patients completed a questionnaire
annually informing whether they had experienced any vascular
event or had been hospitalized in the past year at 1, 2, and 3
years after surgery. Positive answers were validated by further
inquiries according to a standard scheme; discharge letters
and, if needed, laboratory measurements and results of
additional studies, such as electrocardiograms or imaging
studies, were collected from the institution where the
potential event occurred. If patients did not respond to the
follow-up questionnaire, their general practitioner was con-
tacted. Each outcome event was agreed on by consensus of 2
members of the Outcome Assessment Committee or by the
majority decision of 3 members.
Deﬁnition of Outcome
The primary outcome was deﬁned as any MACE. This included
any cardiovascular-related death and nonfatal myocardial
infarction or stroke. In addition, a subgroup was distinguished
for any recurrent stroke.
Histological and Biochemical Measurements
The study design and the standardized protocol of the
Athero-Express Biobank with respect to plaque processing
have been reported previously.18,22 The segment with the
greatest plaque burden was considered to be the culprit
lesion and subjected to histological examination by staining
the section for CD68, smooth muscle actin (SMA), Picro
Sirius Red (PSR), and hematoxylin-eosin (H-E). Macrophage
and smooth muscle cell inﬁltration were quantitatively
scored using computerized analyses (AnalySIS 3.2, Soft
Imaging Systems GmbH, Munster, Germany) as well as
semiquantitatively as “no,” “minor,” “moderate,” or “heavy.”
The amount of collagen (PSR) and calciﬁcation (H-E) were
semiquantitatively scored as “no,” “minor,” “moderate,” or
“heavy” staining. Collagen content was estimated from the
PSR sections with polarized light. The size of the lipid core
was visually estimated at 940 magniﬁcation. The lipid core
size was analyzed in the H-E section, expressed as the
percentage of total plaque area, and scored in 3 categories:
“no fat,” “<40%,” and “>40%” of the total plaque area. The
lipid core consisted of predominantly cholesterol clefts.
Plaque hemorrhage was deﬁned as the composite of plaque
bleeding at the luminal side of the plaque as a result of
plaque disruption and intraplaque hemorrhage, which is
observed as a hemorrhage within the tissue of the plaque.
Plaque hemorrhage was examined in H-E– and ﬁbrin-stained
samples and rated as being absent or present. Intraplaque
vessels were stained with a CD34 antibody. Plaque vessel
density was determined by the average number of vessels of
3 hotspots within every single plaque. A hot spot was
deﬁned as 1 high-power ﬁeld at 940 magniﬁcation. For
vessel quantiﬁcation, we used a grid (1009100 lm) over-
lying every hot spot to improve the reproducibility and to
avoid counting vessels twice. The vessel density was
determined by counting the number of vessels crossed by
a bar of the grid within the selected hot spots. Increased
vessel density was deﬁned as an average vessel count per
hot spot higher than the median of the cohort. The
histological examination was performed by one senior
analyst, who was blinded for the study of MMP-12–positive
macrophages and clinical outcome.
MMP-2, MMP-8, MMP-9, and cleaved caspase-3 activity
levels were determined in proteins isolated from the segment
adjacent to the culprit lesion, as previously reported.20,21
Total activity of MMP-2, MMP-8, and MMP-9 was determined
with use of Biotrak activity assays RPN2631, RPN2635, and
RPN2634, respectively (Amersham Biosciences, Buckingham-
shire, UK). To assess levels of apoptosis within atheroscle-
rotic lesions, activity of cleaved caspase-3 was determined
with luminescent assay (Promega Corporation, Madison,
Wisc).
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Histological Staining Procedure and Image
Analysis to Determine the Proportion
of MMP-12–Positive Macrophages
Two adjacent sections, taken from the culprit lesion, were
immunohistochemically stained for macrophages (CD68) and
MMP-12, by using the following protocol:
Sections were dewaxed, by using Clearane (Leica Biosys-
tems, Peterborough, UK) and rehydrated by using graduated
concentrations of ethanol. Endogenous peroxidase activity
was inhibited by incubating the sections with 0.3% H2O2 for
7 minutes. After rinsing, sections were heated in 10 mmol/L
citrate buffer (pH 6.0) for 2 periods of 6 minutes. Sections
were ﬁrst incubated for 30 minutes with 10% goat serum.
Second, sections were incubated overnight in a cold room
with the primary antibody: CD68 mouse anti-human (DAKO,
Glostrup, Denmark) and MMP-12 rabbit anti-human antibody
(Abcam, Cambridge, UK). After overnight incubation, sections
were washed and incubated with an appropriate biotinylated
secondary antibody: CD68 secondary antibody: goat anti-
mouse (DAKO) or MMP-12 secondary antibody: goat anti-
rabbit (DAKO). Sections were incubated with extravidin–
horseradish peroxidase (Sigma Aldrich, St Louis, MO) and
stained with 3,3′-diaminobenzidine (Sigma Aldrich). Finally,
sections were counterstained with hematoxylin.
Procedure to Quantify the Amount
of MMP-12–Positive FCMs
Semiautomated digital quantiﬁcation
To quantify the presence of MMP-12–positive macrophages
within a relative large amount of samples, we developed a
new, semiautomated method. Sections were digitally scanned
by using a digital scanner (ScanScope XT, Aperio, Vista, CA,
USA). The scanning, storage, and data processing processes
have been described in detail.23 Pictures were made by using
the Aperio software program (Scanscope, Aperio). First, 3
snapshots of CD68-rich areas were taken from the CD68-
stained section, by using a deﬁned rectangle (Video S1), while
blind to the MMP-12 staining. Second, snapshots were taken
of the same area of the MMP-12–stained section (Video S2).
Thirty-seven of the 236 patients did not have a correct
scanned slide, due to problems with focus. Therefore, we used
a light microscope (Olympus UK Ltd, Soutend-On-Sea, UK)
and took snapshots of the atherosclerotic plaque in the same
manner. The amount of positive surface area was quantiﬁed
for each snapshot by using Cell P digital analysis software
(version 2.8, Olympus Soft Images Solutions GbmH). Since
only foamy macrophages stained for MMP-12, the ratio of
foam cells that were positive for MMP-12 was calculated by
dividing the total amount of positive area of the MMP-12
section with the total amount of positive area in the CD 68
section and multiplying by 100. Interobserver and intraob-
server scores were good; the differences between the 2
measurements were within the limits of agreement, as
reported previously by Bland and Altman.24 Analysis was
performed by one researcher (V.S.). Sections that were
damaged (5 sections) or not stained properly (3 sections)
were excluded for analysis.
Manual quantiﬁcation
To verify this semiautomated technique we used a more
laborious individual cell counting procedure in a subgroup of
62 samples. All MMP-12–positive cells were also positive for
CD68 and appeared foamy. Hence, all the MMP-12–positive
cells were counted in the ﬁrst section and all the CD68-
positive cells were counted in the second section, and the
ratio was calculated and multiplied by 100 to give percentage
positivity of CD68 cells for MMP-12. All analyses were
performed by a single observer (N.J.).
Dual Immunohistochemistry and Image Analysis
Three adjacent sections, taken from the culprit lesion, were
immunohistochemically stained with primary antibodies for
MMP-12 and either cleaved caspase-3 (goat anti-human; R&D
Systems, Abingdon, UK), MMP-8 (mouse anti-human; Merck
Millipore, Watford, UK), or MMP-9 (mouse anti-human; Merck
Millipore). Fluorophore conjugated secondary antibodies were
used to yield either a red ﬂuorescent product at the site of the
antigen (Alexaﬂuor 594 for MMP-12) or a green ﬂuorescent
product at the site of the antigen (Alexaﬂuor 488 for cleaved
caspase-3, MMP-8, and MMP-9). Sections were then mounted
in ProLong Gold Antifade Reagent with 4′,6-diamidino-2-
phenylindole (Life Technologies, Paisley, UK; P-36931) to
ﬂuorescently label nuclei blue. The speciﬁcity of the immu-
nolabeling was demonstrated by inclusion of a negative
control using isotype-speciﬁc nonimmune serum or IgG. The
percentage of MMP-12–positive macrophages that stained for
other proteins was counted within each lesion (n=15).
Statistics and Data Analysis
For statistical analyses, PASW statistics 17.0 was used (SPSS
Inc, Chicago, Ill). The percentage of MMP-12–positive macro-
phages was not normally distributed. Clinical and histological
plaque characteristics were analyzed by using a Mann–
Whitney U test (2 groups) or Kruskal–Wallis test (≥3 groups).
Continuous variables were analyzed by using Spearman’s rank
correlation test. Ordinal values versus ordinal values were
analyzed with an ordinal regression analysis. Survival analysis
was performed by using a Cox regression analysis including
MMP-12 quartiles and traditional risk factors that had been
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demonstrated to be signiﬁcantly associated with outcome
(P<0.05). Determinants with P<0.05 were regarded as
statistically signiﬁcant. The authors had full access to and
take full responsibility for the integrity of the data. All authors
have read and agree to the article as written.
Results
Quantiﬁcation of the MMP-12–Positive FCM
Subpopulation
Culprit lesions were obtained from 236 patients who under-
went CEA, whose characteristics are summarized in Table 1,
columns 1 and 2. Serial sections were immunostained for
MMP-12 and CD68 (Figures 1 and 2). Nonimmune controls
revealed that the staining was speciﬁc (Figure 1D compared
with 1F). The majority of MMP-12–positive cells were located
in deeper parts of the plaque surrounding the necrotic cores,
in agreement with previous work (Figure 1A and 1B).12 In such
areas, MMP-12 staining was located exclusively in CD68-
positive cells with a foamy appearance, that is, in FCMs.
Furthermore, whereas most CD68-positive FCMs around the
core stained for MMP-12 (Figures 1C, 1D, and 2B), very few
CD68-positive cells stained for MMP-12 in other plaque areas
(Figure 2D). We concluded that MMP-12 was expressed only
in a subpopulation of FCMs, which conﬁrmed the results of
previous studies.12
To quantify the MMP-12–positive subpopulation, we
selected 3 ﬁelds with abundant CD68 staining and measured
the CD68-positive area while still blind to the MMP-12 staining
(Figure 2A and 2C, Video S1). We then measured the area of
MMP-12 staining in the corresponding ﬁelds of the serial
section (Figure 2B and 2D, Video S2) and computed the MMP-
12/CD68 ratio as a percentage. The average value for the 3
areas was assigned to each patient. To validate this semiau-
tomated histological analysis, we selected serial sections from
62 plaques, of which 28 were deﬁned as ﬁbrous plaques and
34 were deﬁned as atheromatous plaques, according to the
Athero-Express protocol and subjected these to a more
laborious cell-counting method. All the MMP-12– and CD-
68–positive cells were counted and the ratio was computed.
The 2 methods showed a high level of correlation (r=0.744,
P<0.001), and the differences between them were within the
limits of agreement, as described by Bland and Altman.24
Baseline Characteristics
With respect to the clinical baseline data, we found that
plaques from female patients had a signiﬁcantly lower
percentage of MMP-12–positive macrophages compared with
plaques from male patients (Table 1). In addition, plaques
from patients with a previous coronary intervention or
myocardial infarction had a signiﬁcantly higher percentage
of MMP-12–positive macrophages (Table 1).
Table 1. Patient Characteristics and Their Relationship to the Percentage of MMP-12–Positive Macrophages
Characteristic Total Cohort, n (%)
MMP-12/CD68 ratio
PNo Yes
Age >69 y (median) 1.9 [0 to 29.0] 1.8 [0 to 22.9] 0.539
Male sex 178 (75.4) 0.4 [0 to 7.9] 4.4 [0 to 34.1] 0.004
Hypertension 176 (74.6) 0.5 [0 to 15.4] 2.6 [0 to 28.3] 0.127
Diabetes 40 (16.9) 1.8 [0 to 24.7] 5.2 [0 to 28.7] 0.645
Hypercholesterolemia 132 (55.9) 1.8 [0 to 18.4] 1.9 [0 to 31.7] 0.470
Smoking* 81 (34.3)* 3.3 [0 to 27.6] 1.0 [0 to 24.7] 0.452
Positive family history† 59 (26.9)† 1.2 [0 to 17.7] 5.5 [0 to 29.0] 0.173
History of myocardial infarction 30 (12.7) 1.8 [0 to 20.7] 19.4 [0.2 to 58.4] 0.043
History of coronary intervention 54 (22.9) 1.2 [0 to 20.7] 4.8 [0.2 to 59.0] 0.031
Previous myocardial infarction or coronary intervention 66 (28.0) 1.2 [0 to 18.0] 6.0 [0.2 to 53.3] 0.017
History of peripheral intervention 44 (18.6) 1.9 [0 to 24.5] 1.5 [0 to 33.2] 0.929
Previous stroke 27 (11.4) 1.8 [0 to 24.4] 1.8 [0 to 51.9] 0.952
Asymptomatic vs symptomatic 41(17.4) vs 195 (82.6) 1.0 [0 to 27.6] 1.9 [0 to 24.6] 0.445
Asymptomatic vs AFX 41(17.4) vs 29 (12.3) 1.0 [0 to 27.6] 4.1 [0 to 42.2] 0.778
Transient ischemic attack vs stroke 110 (46.6) vs 56 (23.7) 1.9 [0 to 25.1] 1.8 [0 to 24.1] 0.862
Median values and quartile 1 to quartile 3 (between brackets) of MMP-12 ratio are depicted for patients without or with a characteristic. AFX indicates amaurosis fugax.
*The smoking status of 2 patients could not be retrieved.
†The family history of 17 patients could not be retrieved.
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Based on values from all the plaques, the percentage of
MMP-12–positive macrophages was signiﬁcantly associated
with the amount of lipid core (Figure 3, Table 2) and with
the amount of macrophages, as measured both semi-
quantitatively (Figure 3, Table 2) and quantitatively (r=0.436,
n=235, P<0.001). The prevalence of MMP-12–positive
macrophages negatively correlated with the presence of SMCs
(Figure 3, Table 2). We did not observe a signiﬁcant
relationship between MMP-12–positive macrophages and cal-
ciﬁcations, the amount of collagen, or the presence of
thrombus or intraplaque hemorrhage (Table 2). On the basis
of these data, we concluded that a higher proportion of
MMP-12–positive FCMs are present in highly inﬂamed, lipid-
rich plaques with relatively reduced smooth muscle cell
content. Furthermore, the MMP-12–positive FCM sub-
population signiﬁcantly correlated with activity of MMP-8
(r=0.211, n=233, P=0.001), MMP-9 (r=0.251, n=233,
P<0.001), and cleaved caspase-3 (r=0.142, n=217, P=0.036),
a marker of apoptosis, but not with MMP-2 (r=0.104, n=235,
P=0.114) measured in lysates of the segment adjacent to the
culprit lesion taken from the same plaques (Table 2). Dual
immunohistochemistry demonstrated that MMP-12–positive
FCMs were a subpopulation of the MMP-8– and MMP-9–
positive FCMs in these CEA plaques (Figure 4). Although few
cleaved caspase-3–positive macrophages were found, these
were all located near the necrotic core (Figure 5) and all were
MMP-12 positive. This implies that all apoptotic FCMs arose
from the MMP-12–positive subpopulation (Figure 5).
Relationship With Clinical Outcome
The estimates of percentages of MMP-12–positive macro-
phages were not normally distributed (Figure 2E); hence, for
further statistical analysis, the patients were divided into
Figure 1. Immunocytochemistry for MMP-12 and CD68 in human atherosclerotic plaques. A, A plaque section stained with antibodies against
MMP-12 (magniﬁcation 940). B, A section of a different plaque stained as in A. C, The boxed area of A (magniﬁcation 9400). D, The boxed area of
B (magniﬁcation 9400). E, The corresponding area in C in a serial section stained with anti-CD68. F, The corresponding area in D in a serial
section stained with nonimmune IgG. The bar within A and B represents 1 mm, and the bar within C to F represents 0.1 mm.
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quartiles, based on the MMP-12/CD68 ratio taken for their
plaque sections (Figure 2F).
In our chosen sample, 55 (23%) patients developed an
MACE during 3 years of follow-up and 27 (11%) patients
sustained a stroke. The occurrence of MACEs and strokes
across the 4 quartiles of MMP-12 positivity is shown in
Table 3. Patients within the highest quartile of MMP-12–
positive macrophages had a 2.4-fold increased risk to
develop an MACE (hazard ratio, 2.4; 95% CI, 1.1 to 5.1;
adjusted P=0.027) compared with patients within the lowest
quartile (Table 3, Figure 6A). This risk increased to 3.4 for
stroke (3.4; 1.2 to 9.6; P=0.024) (Table 3, Figure 6B). The
results of univariate and multivariate analyses taking into
account baseline characteristics are shown in Table 4.
Importantly, although the prevalence of the MMP-12–
positive subpopulation predicted adverse outcome, the total
number of (CD68-positive) FCMs did not correlate with
clinical outcome, as previously reported (Figure 6C and
6D).18
Discussion
Main Findings
We are, to our knowledge, the ﬁrst to report that presence of
a speciﬁc subset of FCMs in plaques predicts adverse patient
outcome. Using a relatively large cohort of patients, we show
that the proportion of MMP-12–positive FCMs is higher in CEA
tissues from patients who sustained adverse clinical out-
comes during 3 years of follow-up.
Figure 2. Comparison of MMP-12– and CD68-stained areas in CEA specimens. A, An example of a CD68-positive area of interest selected for
analysis while blind to the MMP-12 staining. B, The serial section stained for MMP-12. Most CD68 cells are also MMP-12 positive. C, A different
CD68-positive area of interest selected for analysis. D, The area in C stained for MMP-12 in a serial section. Most CD68-positive cells are negative
for MMP-12. E, The distribution of MMP-12–positive macrophages across all the patients. F, A box-whisker plot showing the values of MMP-12
positivity in the 4 quartiles. The bar within A to D represents 0.2 mm.
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MMP-12 and Vulnerable Plaque Features
Animal and human studies have demonstrated that MMP-12 is
absent in healthy arteries, minimally present in early lesions,
and strongly expressed in advanced atherosclerotic pla-
ques.8,9,12–14 However, the relationship between the presence
of MMP-12–positive macrophages and markers of plaque
vulnerability has remained uncertain. To quantify the percent-
age of MMP-12–positive macrophages within a relatively large
number of samples, we developed a new, semiautomated
method and validated this against a more laborious manual
counting method. The percentage of MMP-12–positive macro-
phages was associated with vulnerable plaque features,
namely the presence of large lipid cores and abundance of
macrophages, and negatively with the presence of smooth
muscle cells, which is considered a feature of a more stable
plaque phenotype.25 The percentage of MMP-12–positive
macrophages was not signiﬁcantly related to other histolog-
ical features of vulnerable plaques such as the presence of
thrombus or intraplaque hemorrhage, perhaps as a result of
inadequate statistical power.
Table 2. Percentage of MMP‐12 positive macrophages in relation to semi‐quantitative plaque characteristics
Plaque feature No/Minor n Moderate n Heavy n P
Calciﬁcations 1.2 [0–20] 107 2.6 [0–38] 73 1.8 [0–22] 56 0.716
Collagen 1.2 [0–32] 56 2.2 [0–26] 128 1.9 [0–22] 52 0.610
Macrophages 0.1 [0–6] 111 11.4 [0–45] 81 13.8 [2–66] 44 <0.001
Smooth muscle cells 5.6 [0–27] 82 1.8 [0–34] 106 0.1 [0–15] 48 0.036
Plaque feature Absent n Present n P
Lipid core > 40% 1.0 [0–17] 146 8.0 [0–43] 90 0.001
Increased vessel density (> median)* 1.8 [0–29] 113 2.9 [0–25] 110 0.775
Intra‐plaque Haemorrhage 1.1 [0–23] 159 5.4 [0–32] 77 0.134
Thrombus composite 0.4 [0–23] 69 2.4 [0–25] 167 0.343
Plaque feature R P Plaque feature R P
Macrophages (quantitatively) 0.436 < 0.001 MMP‐2 0.104 0.114
Smooth Muscle Cells (quantitatively) ‐0.053 0.425 MMP‐8 0.211 0.001
Vessel density* 0.034 0.609 MMP‐9 0.251 <0.001
Caspase‐3 0.142 0.036
Median values of MMP‐12/CD68 area x 100 are provided for different plaque features, with Q1–Q3 depicted between parentheses, and the number of observations (n) in the preceding
column. Quantitatively determined plaque features are depicted in the last rows, together with the correlation coefﬁcient (Spearman) and P-value.
*Vessel density was not determined for 13 patients.
A B
Figure 3. Vulnerable plaque characteristics and the percentage of patients within the 4 quartiles of MMP-12–positive macrophages. A, The
amount of lipid core (abbreviated to fat) within the plaque was semiquantitatively scored. B, The amount of macrophages, also semiquantitatively
scored. ***P<0.001 ordinal regression.
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The hypothesis that MMP-12 is causal in, rather than
merely a marker of, plaque instability is borne out by a
substantial body of experimental animal research. For exam-
ple, work from our group and another5,10 found that MMP-12
knockout in apolipoprotein E–deﬁcient mice reduces lesion
progression, macrophage inﬁltration, lipid core formation,
calciﬁcation, degradation of elastic lamellae, and the
development of buried ﬁbrous layers that may reﬂect silent
plaque ruptures. Work in transgenic rabbits also shows that
active MMP-12 can promote the development of advanced
plaques.8 In the present study, we showed that macrophages
positive for MMP-12, which is a metalloelastase, were also
positive for a collagenase, MMP-8, and a gelatinase, MMP-9,
which we have previously reported are strongly related with a
more vulnerable plaque phenotype.20,21 Together, these 3
MMPs have a broad speciﬁcity for extracellular matrix
components, which may add to their destructive potential.
Apart from destruction of the extracellular matrix, MMPs can
also cleave nonmatrix components, leading to modulation of
the migration, proliferation, and apoptosis of vascular cells.26
A B
C D
MMP-8 MMP-12
DAPI Merged
E F
G H
MMP-9 MMP-12
DAPI Merged
Figure 4. Immunohistochemical staining of adjacent segments for (A) MMP-8, (B) MMP-12, (C) 4′,6-diamidino-2-phenylindole (DAPI), and D
merged and for (E) MMP-9, (F) MMP-12, (G) DAPI, and (H) merged: demonstrating colocalization of MMP-12 with MMP-8 and MMP-9.
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In this context, it is particularly interesting to note the
recently reported ability of MMP-12 to promote apoptosis of
mouse and human macrophages.11 This may explain why, in
our study, we found that cleaved caspase-3 levels correlated
and colocalized with MMP-12–positive macrophages. Macro-
phage apoptosis contributes to lipid core formation,27 which,
as noted, was also associated with MMP-12 positivity in our
study. Our results, therefore, at least show that MMP-12 may
be causative in plaque macrophage apoptosis, promoting
plaque progression and instability by augmenting lipid core
formation.
MMP-12 and Clinical Parameters
Compared with female patients, male patients are more prone
to develop cardiovascular events during life and are at
increased risk for recurrent cardiovascular events,2,28 as also
shown in our present study (Table 4). Furthermore, we
observed a signiﬁcantly lower prevalence of MMP-12–positive
FCMs within the carotid plaques of female patients (Table 1).
We have previously reported that female patients have more
stable atherosclerotic plaques with less lipid andmacrophages,
more smooth muscle cells, and higher collagen content.29 In
addition, levels of interleukin-8 and MMP-8 activity were found
to be lower. From our present data, lowered prevalence of
MMP-12–positive macrophages appears to be another factor
possibly related to the protective effect of female sex on
atherosclerosis.
We clearly demonstrated that the proportion of MMP-
12–positive FCMs was greater in patients who had
undergone CEA and developed secondary cardiovascular
events during follow-up. Patients within the fourth quartile
of MMP-12–positive macrophages had, compared with
patients within the lowest quartile, a 2.4-times increased
risk of an MACE and a 3.4-times increased risk of a stroke.
Although the number of strokes was low and the observed
increased risk has to be interpreted with caution, these
differences persisted after correction for age and sex. The
differences in outcome were mainly apparent between
patients within the ﬁrst quartile, whose plaques had no
MMP-12–positive FCMs, and those within the fourth
quartile, for whom >25% of FCMs were positive for MMP-
12 (Figure 2F, Table 3).
Atherosclerosis is a systemic disease30 and plaque
composition is related between different arterial territories
A B
C D
CC3 MMP-12
DAPI Merged
Figure 5. Immunohistochemical staining for (A) cleaved caspase-3 (CC3), (B) (MMP-12), (C) nuclear staining (4′,6-diamidino-2-phenylindole
[DAPI]), and (D) merged, demonstrating colocalization of CC3 with MMP-12. All CC3-positive cells were also positive for MMP-12.
Table 3. Clinical Outcome and the Presence of MMP-12–
Positive Macrophages
Quartile Major End Point, n (%) Stroke End Point, n (%)
First 16 7
Second 25 15
Third 24 14
Fourth 31 20
P-value (ﬁrst vs fourth) 0.027 0.024
Patients were divided into quartiles based on their percentage of MMP-12–positive
macrophages. The percentage of patients who developed an end point and the P-values
adjusted for sex and age (major end point) and age (stroke) are depicted.
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in a given patient.31 It is not surprising, therefore, that
atherosclerotic plaques sampled from one location might
contain markers predictive for future cardiovascular events
in other parts of the arterial tree. We previously reported
that several proteins expressed in local plaques and some
histological features, including intraplaque hemorrhage and
microvessel density, can provide prognostic information for
the occurrence of events in other vascular territo-
ries.17,19,20 Interestingly, however, we reported that the
total amount of CD68-positive FCMs in CEA plaques is not
associated with adverse clinical outcome,18 as conﬁrmed
in our study (Figure 6C and 6D). Hence, our new data
showing that the presence of a speciﬁc FCM subtype
expressing MMP-12 is associated with adverse clinical
outcome are not confounded by its relationship to total
numbers of FCMs.
Conclusions
Our results show for the ﬁrst time that a subset of
macrophages expressing MMP-12 in human atherosclerotic
plaques are associated with vulnerable plaque characteristics
and adverse clinical outcome. This new information adds to
our understanding of the systemic nature of atherosclerotic
disease. It also builds on a substantial body of experimental
evidence from animals to emphasize the potential of MMP-12
as therapeutic target. The ongoing development and reﬁne-
ment of MMP-12–speciﬁc inhibitors amplify the implications
of our study for plaque stabilization therapy. Furthermore,
although clearly beyond the scope of the present study,
MMP-12 activity might form the basis of a method to identify
vulnerable plaques. For example, several studies have estab-
lished the practicality of imaging MMP activity in plaques.32,33
Table 4. Univariate and Multivariate Cox Regression Analyses of Risk Factors and MMP-12 Quartiles
Clinical Characteristic
Univariate Cox Regression Multivariate Cox Regression (Enter)
P HR (CI) P HR (CI)
Major end point
Sex 0.039 2.309 [1.045 to 5.104] 0.108
Age <0.001 1.080 [1.044 to 1.118] <0.001 1.086 [1.047 to 1.126]
Smoking* 0.996
Diabetes 0.224
Hypertension 0.987
Hypercholesterolemia 0.521
Family history of heart disease† 0.452
GFR‡ 0.217
MMP-12/CD68 ratio (quartiles) 0.242
Fourth vs ﬁrst quartile 0.042 2.182 [1.030 to 4.624] 0.027 2.369 [1.104 to 5.083]
Stroke end point
Sex 0.448
Age 0.002 1.074 [1.027 to 1.123] 0.001 1.080 [1.031 to 1.132]
Smoking* 0.462
Diabetes 0.388
Hypertension 0.344
Hypercholesterolemia 0.420
Family history of heart disease† 0.094
GFR‡ 0.835
MMP-12 ratio (quartiles) 0.222
Fourth vs ﬁrst quartile 0.036 3.049 [1.074 to 8.659] 0.024 3.358 [1.176 to 9.583]
P-values and hazard ratios (HRs), with 95% CIs depicted between brackets. Risk factors with a P-value <0.1 were included in the multivariate Cox regression (enter) model to correct for
potential confounding.
*The smoking status of 2 patients could not be retrieved.
†The family history of 17 patients could not be retrieved.
‡The glomerular ﬁltration rate (GFR) of 1 patient could not be retrieved.
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Hence, a technique based on visualizing MMP-12 protein or
its activity using a selective substrate might be possible.
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